{"id":77761,"date":"2026-09-01T12:35:18","date_gmt":"2026-09-01T04:35:18","guid":{"rendered":"https:\/\/flcube.com\/?p=77761"},"modified":"2026-09-01T12:35:19","modified_gmt":"2026-09-01T04:35:19","slug":"shanghai-raass-sr604-enters-nmpa-cde-rare-disease-encouragement-program-for-hemophilia-and-factor-vii-deficiency-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77761","title":{"rendered":"Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment"},"content":{"rendered":"\n

China’s Shanghai RAAS (SHE: 002252<\/a>)<\/strong> announced that its candidate SR604<\/strong> has been included by the Center for Drug Evaluation (CDE)<\/strong> of the National Medical Products Administration (NMPA)<\/strong> into the Encouragement Pilot Program for Innovative Rare Disease Drug R&D<\/strong> (“Caring Program – Extension<\/strong>“). The designation recognizes SR604 Injection<\/strong>, a novel humanized monoclonal antibody intended for the prophylactic treatment of bleeding<\/strong> in patients with hemophilia<\/strong> and congenital factor VII deficiency<\/strong>, as a priority innovation in China’s rare disease landscape.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/td>Center for Drug Evaluation (CDE)<\/strong> of the National Medical Products Administration (NMPA)<\/strong><\/td><\/tr>
Designation<\/td>Encouragement Pilot Program for Innovative Rare Disease Drug R&D<\/strong> (“Caring Program – Extension”)<\/td><\/tr>
Product<\/td>SR604 Injection<\/strong> (humanized monoclonal antibody)<\/td><\/tr>
Indication<\/td>Prophylactic treatment of bleeding in hemophilia<\/strong> and congenital factor VII deficiency<\/strong><\/td><\/tr>
Sponsor<\/td>Shanghai RAAS (SHE: 002252)<\/strong><\/td><\/tr>
Date<\/td>28 Aug 2026<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n